Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma

Clinical and Experimental Allergy

Volumn 38, Issue 5, 2008, Pages 847-856

  Herbert, C ^a   Hettiaratchi, A ^a   Webb, D C ^b   Thomas, P S ^c   Foster, P S ^b,d   Kumar, R K ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Biology and Environment   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Airway inflammation; Airway remodelling; Cytokines; Phosphodiesterase 4 inhibitors; Th17 cells

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; INTERLEUKIN 6; OVALBUMIN; ROFLUMILAST; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG INHIBITION; FEMALE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY EPITHELIUM; T LYMPHOBLAST;

AMINOPYRIDINES; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BENZAMIDES; BRONCHI; CHRONIC DISEASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYCLOPROPANES; CYTOKINES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, INBRED BALB C; PHOSPHODIESTERASE INHIBITORS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 42249111884     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2008.02950.x     Document Type: Article

References (49)

1. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000 161 : 1720 45.
2. Riffo-Vasquez Y, Spina D. Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation. Pharmacol Ther 2002 94, 185 211.
3. Larche M, Robinson DS, Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003 111 : 450 63.
4. Lee CG, Homer RJ, Zhu Z et al. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001 194, 809 21.
5. Kumar RK, Herbert C, Foster PS. Expression of growth factors by airway epithelial cells in a model of chronic asthma: regulation and relationship to subepithelial fibrosis. Clin Exp Allergy 2004 34 : 567 75.
6. Heaton T, Rowe J, Turner S et al. An immunoepidemiological approach to asthma: identification of in-vitro T-cell response patterns associated with different wheezing phenotypes in children. Lancet 2005 365 : 142 9.
7. Bullens DM, Truyen E, Coteur L et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006 7 : 135.
8. Hamelmann E, Cieslewicz G, Schwarze J et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med 1999 160, 934 41.
9. Henderson WR Jr., Chi EY, Maliszewski CR. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000 164 : 1086 95.
10. O'Byrne PM, Inman MD, Adelroth E. Reassessing the Th2 cytokine basis of asthma. Trends Pharmacol Sci 2004 25 : 244 8.
11. Ichinose M, Barnes PJ. Cytokine-directed therapy in asthma. Curr Drug Targets Inflamm Allergy 2004 3 : 263 9.
12. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998 157 : S1 53.
13. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther 2001 297, 280 90.
14. van Schalkwyk E, Strydom K, Williams Z et al. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol 2005 116 : 292 8.
15. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998 53 : 849 56.
16. Cohn L. Food for thought: can immunological tolerance be induced to treat asthma? Am J Respir Cell Mol Biol 2001 24 : 509 12.
17. Fulkerson PC, Rothenberg ME, Hogan SP. Building a better mouse model: experimental models of chronic asthma. Clin Exp Allergy 2005 35 : 1251 3.
18. Kumar RK, Foster PS. Modeling allergic asthma in mice: pitfalls and opportunities. Am J Respir Cell Mol Biol 2002 27 : 267 72.
19. Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy 2002 32, 1104 11.
20. Kumar RK, Herbert C, Webb DC, Li L, Foster PS. Effects of anticytokine therapy in a mouse model of chronic asthma. Am J Respir Crit Care Med 2004 170 : 1043 8.
21. Kumar RK, Herbert C, Thomas PS et al. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma. J Pharmacol Exp Ther 2003 307 : 349 55.
22. Kumar RK, Thomas PS, Seetoo DQ et al. Eotaxin expression by epithelial cells and plasma cells in chronic asthma. Lab Invest 2002 82 : 495 504.
23. Foster PS, Yang M, Herbert C, Kumar RK. CD4(+) T-lymphocytes regulate airway remodeling and hyper-reactivity in a mouse model of chronic asthma. Lab Invest 2002 82 : 455 62.
24. Foster PS, Ming Y, Matthei KI, Young IG, Temelkovski J, Kumar RK. Dissociation of inflammatory and epithelial responses in a murine model of chronic asthma. Lab Invest 2000 80 : 655 62.
25. Kenyon NJ, Ward RW, Last JA. Airway fibrosis in a mouse model of airway inflammation. Toxicol Appl Pharmacol 2003 186 : 90 100.
26. Webb DC, McKenzie AN, Koskinen AM, Yang M, Mattes J, Foster PS. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000 165 : 108 13.
27. Foster PS, Webb DC, Yang M, Herbert C, Kumar RK. Dissociation of T helper type 2 cytokine-dependent airway lesions from signal transducer and activator of transcription 6 signalling in experimental chronic asthma. Clin Exp Allergy 2003 33 : 688 95.
28. Claveau D, Chen SL, O'Keefe S et al. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4- Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxy propan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 2004 310, 752 60.
29. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001 297 : 267 79.
30. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 24 : 677 88.
31. Schmidt-Weber CB, Akdis M, Akdis CA. TH17 cells in the big picture of immunology. J Allergy Clin Immunol 2007 120 : 247 54.
32. Langrish CL, Chen Y, Blumenschein WM et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 201 : 233 40.
33. Alber G, Kamradt T. Regulation of protective and pathogenic Th17 responses. Curr Immunol Rev 2007 3 : 3 16.
34. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007 19 : 281 6.
35. Kwak HJ, Song JS, Heo JY, Yang SD, Nam JY, Cheon HG. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther 2005 315 : 1188 95.
36. Lazzeri N, Belvisi MG, Patel HJ, Yacoub MH, Chung KF, Mitchell JA. Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. Am J Respir Cell Mol Biol 2001 24 : 44 8.
37. Shah A, Church MK, Holgate ST. Tumour necrosis factor alpha: a potential mediator of asthma. Clin Exp Allergy 1995 25 : 1038 44.
38. Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006 354 : 697 708.
39. Ritz SA, Stampfli MR, Davies DE, Holgate ST, Jordana M. On the generation of allergic airway diseases: from GM-CSF to Kyoto. Trends Immunol 2002 23 : 396 402.
40. Tang C, Rolland JM, Li X, Ward C, Bish R, Walters EH. Alveolar macrophages from atopic asthmatics, but not atopic nonasthmatics, enhance interleukin-5 production by CD4+T cells. Am J Respir Crit Care Med 1998 157 : 1120 6.
41. Rubbia-Brandt L, Sappino AP, Gabbiani G. Locally applied GM-CSF induces the accumulation of alpha-smooth muscle actin containing myofibroblasts. Virchows Arch B (Cell Pathol) 1991 60 : 73 82.
42. Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol 1997 158 : 954 9.
43. Elias JA, Zhu Z, Chupp G, Homer RJ. Airway remodeling in asthma. J Clin Invest 1999 104 : 1001 6.
44. Molet S, Hamid Q, Davoine F et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001 108 : 430 8.
45. Linden A. Interleukin-17 and airway remodelling. Pulm Pharmacol Ther 2006 19 : 47 50.
46. Howarth PH. A comparison of the anti-inflammatory properties of intranasal corticosteroids and antihistamines in allergic rhinitis. Allergy 2000 55 (Suppl. 62) : 6 11.
47. Hidi R, Timmermans S, Liu E et al. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. Eur Respir J 2000 15 : 342 9.
48. Dheda K, Huggett JF, Chang JS et al. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Anal Biochem 2005 344 : 141 3.
49. Kelly MM, Leigh R, Bonniaud P et al. Epithelial expression of profibrotic mediators in a model of allergen-induced airway remodeling. Am J Respir Cell Mol Biol 2005 32 : 99 107.